Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer

Table 2

Prognostic value of combined miR-15a and miR-16 expression for the disease-free survival and overall survival in univariate and multivariate analyses by Cox regression.

	Disease-free survival		Overall survival
	Hazard ratio (95% CI)		Hazard ratio (95% CI)
Univariate
Gender	1.005 (0.101–2.208)	NS	1.298 (0.122–2.891)	NS
Age	1.091 (0.198–2.623)	NS	1.255 (0.226–2.879)	NS
Site of primary tumor	0.698 (0.119–5.516)	NS	0.869 (0.126–1.881)	NS
Tumor size	0.379 (0.103–0.743)	NS	0.799 (0.136–1.606)	NS
Depth of tumor invasion	0.462 (0.102–1.039)	NS	0.729 (0.108–1.692)	NS
Lymph node metastasis	3.232 (1.566–6.676)	0.01	3.528 (1.616–7.869)	0.008
TNM stage	5.069 (1.981–12.620)	<0.001	5.869 (1.996–12.788)	<0.001
Histological grade	3.982 (1.119–8.116)	0.006	4.569 (1.126–10.281)	0.001
miR-15a	4.336 (1.201–9.682)	0.001	4.628 (1.128–10.161)	0.001
miR-16	4.283 (1.123–9.416)	0.001	4.562 (1.121–10.286)	0.001
miR-15a/miR-16	5.019 (1.972–12.069)	<0.001	5.712 (1.982–12.689)	<0.001
Multivariate
Lymph node metastasis	2.058 (1.013–4.621)	0.02	2.655 (1.039–5.528)	0.01
Histological grade	2.698 (1.119–5.516)	0.01	2.869 (1.126–5.881)	0.01
miR-15a	2.782 (1.122–6.031)	0.01	3.016 (1.129–6.616)	0.01
miR-16	2.598 (1.013–6.006)	0.01	2.912 (1.110–6.011)	0.01
miR-15a/miR-16	4.818 (1.937–10.129)	<0.001	4.983 (1.946–10.962)	<0.001